E
Emmanuelle Polge
Researcher at Pierre-and-Marie-Curie University
Publications - 77
Citations - 3423
Emmanuelle Polge is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Transplantation & Acute leukemia. The author has an hindex of 24, co-authored 67 publications receiving 2832 citations. Previous affiliations of Emmanuelle Polge include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
Christoph Schmid,Myriam Labopin,Arnon Nagler,Martin Bornhäuser,Jürgen Finke,Athanasios Fassas,Liisa Volin,Gunham Gurman,Johan Maertens,Pierre Bordigoni,Ernst Holler,Gerhard Ehninger,Emmanuelle Polge,Norbert Claude Gorin,Hans-Jochem Kolb,Vanderson Rocha +15 more
TL;DR: The results confirm that the clinical benefit of donor lymphocyte infusion in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (HSCT) is limited to a minority of patients.
Journal ArticleDOI
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
M. Aoudjhane,Myriam Labopin,Norbert-Claude Gorin,A. Shimoni,T. Ruutu,H.-J. Kolb,Francesco Frassoni,J. M. Boiron,J. L. Yin,Jürgen Finke,H. Shouten,D. Blaise,M. Falda,A. A. Fauser,Jordi Esteve,Emmanuelle Polge,S. Slavin,D. Niederwieser,Arnon Nagler,Vanderson Rocha +19 more
TL;DR: Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative regimen HSCT in patients with acute myeloblastic leukaemia over 50 years of age, and these results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.
Journal ArticleDOI
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation
Fabio Ciceri,Myriam Labopin,Franco Aversa,Jakob M. Rowe,Donald Bunjes,Philippe Lewalle,Arnon Nagler,Paolo Bartolomeo,João F. Lacerda,Maria Teresa Lupo Stanghellini,Emmanuelle Polge,Francesco Frassoni,Massimo F. Martelli,Vanderson Rocha +13 more
TL;DR: Haploidentical hematopoietic stem cell transplantation can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a human leukocyte antigen-matched donor.
Journal ArticleDOI
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid,Myriam Labopin,Arnon Nagler,Dietger Niederwieser,Luca Castagna,Reza Tabrizi,Michael Stadler,Jürgen Kuball,Jan J. Cornelissen,Jiri Vorlicek,Gérard Socié,Michele Falda,Lars Vindeløv,Per Ljungman,Graham Jackson,Nicolaus Kröger,Andreas Rank,Emmanuelle Polge,Vanderson Rocha,Mohamad Mohty +19 more
TL;DR: Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation, suggesting that remission duration after transplantation was the only prognostic factor for response.
Journal ArticleDOI
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
Martin Schmidt-Hieber,Myriam Labopin,Dietrich W. Beelen,Liisa Volin,Gerhard Ehninger,Jürgen Finke,Gérard Socié,Rainer Schwerdtfeger,Nicolaus Kröger,Arnold Ganser,Dietger Niederwieser,Emmanuelle Polge,Igor Wolfgang Blau,Mohamad Mohty +13 more
TL;DR: It is concluded that donor and/or recipient CMV seropositivity is still associated with an adverse prognosis in de novo acute leukemia patients after allo-SCT despite the implementation of sophisticated strategies for prophylaxis, monitoring, and (preemptive) treatment of CMV.